Business Context and Reporting Period
Company: 22nd Century Group, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: The Company is a plant biotechnology firm focused on reducing smoking-related disease. Its primary activities include developing X-22 (a botanical smoking cessation aid), modified risk tobacco products, and manufacturing proprietary cigarettes (RED SUN, MAGIC, and SPECTRUM).
Significant Event: On January 25, 2011, the Company completed a reverse merger with 22nd Century Limited, LLC, and simultaneously closed a private placement offering.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Net Sales | $117,456 | $0 |
| Total Gross Revenue (incl. grant) | $166,672 | $0 |
| Net Loss | $(651,666) | $(305,017) |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.04) |
| Cash and Cash Equivalents (End of Period) | $872,401 | $151 |
| Working Capital | $502,654 | $(Negative) |
| Total Current Liabilities | $1,458,997 | $4,823,635 (Dec 31, 2010) |
| Long-Term Debt | $677,000 | $65,557 (Dec 31, 2010) |
| Warrant Derivative Liability | $3,061,750 | $0 |
Material Changes vs. Prior Period
- Revenue Generation: The Company recorded its first revenue in Q1 2011 ($117,456) from a government research cigarette program, compared to zero in Q1 2010. Additionally, $49,216 in therapeutic grant credit was recognized.
- Operating Expenses: Total operating expenses increased significantly to $804,333 from $231,388 in the prior year. This was driven by a 127% increase in R&D (due to Phase II-B clinical trials) and the introduction of Sales and Marketing costs ($171,525) which were previously non-existent.
- Liquidity Improvement: Cash balances surged from $310 at year-end 2010 to $872,401 at March 31, 2011, primarily due to a private placement raising approximately $3.46 million in net proceeds.
- Debt Restructuring: Current liabilities decreased by over $3.3 million from December 31, 2010, as approximately $614,000 of shareholder debt was converted to equity and other obligations were paid down using private placement proceeds.
- Derivative Liability: A new warrant derivative liability of $3.06 million was recorded due to "down round" provisions in warrants issued during the January 2011 private placement.
Outlook, Risks, and Management Commentary
- Capital Needs: Management expects to require additional capital in the fourth quarter of 2011 to fund operations, complete FDA clinical trials for X-22, and pay maturing obligations. Future equity financing will be dilutive.
- Regulatory Timeline: The Company does not expect FDA approval for X-22 until at least the fourth quarter of 2012. It anticipates submitting applications for modified risk tobacco products in 2011, a process expected to take at least one year.
- Registration Rights Constraint: The Company cannot sell new equity securities for 90 days following the effective date of the registration statement for shares issued in the January 2011 private placement. This statement must be effective by December 4, 2011, or penalties will apply.
- Key Risks:
- Liquidity: Continued operating losses and the need for future financing create a risk of inability to continue as a going concern if funds are not raised.
- License Agreement: The Company owes North Carolina State University (NCSU) approximately $728,000 for patent costs. While a deferred payment arrangement is proposed, failure to agree could lead to termination of the exclusive license.
- Bank Loan Compliance: The Company has not complied with the annual "clean-up" provision of its demand bank loan, though the bank has not demanded payment.
Investor Verification Checklist
- Private Placement Terms: Verify the effective date of the registration statement for the 5.4 million shares issued in January 2011 to ensure no penalties are incurred and to confirm when the 90-day lock-up on new equity sales expires.
- NCSU Debt Resolution: Confirm the status of the $728,000 owed to North Carolina State University and whether a formal deferred payment agreement has been executed to prevent license termination.
- Derivative Liability Valuation: Review the assumptions used in the binomial lattice model for the $3.06 million warrant liability, as changes in stock volatility or price could significantly impact future earnings.
- Cash Burn Rate: Monitor the $1.65 million cash used in operating activities in Q1 2011 against the $872,000 cash balance to assess runway before the anticipated Q4 2011 capital raise.
- Bank Loan Status: Verify if the bank has formally waived the "clean-up" provision default or if the loan is in a state of technical default.